CV-14 / Takeda, Cellivery - LARVOL DELTA

Cellivery Receives Life Preservation Results, New Drug for Incurable Diseases Treatment from Global Top 10 Pharmaceutical Companies [Google translation] (Money Today Network (MTN)) - "At the proposal of a global top 10 pharmaceutical company, a cell/tissue-permeable prataxin recombinant protein formulation (CP-FXN) using Cellivery's 'in vivo delivery technology TSDT platform' was developed...'In the pharmacokinetic (PK) test...CP-FXN begins to be transmitted to the heart and brain tissue from 15 minutes after administration, and is transmitted to the highest in 1 hour'...'This disease animal model is a genetically transgenic animal that can simulate a human genetic disease'...It showed a survival rate 2.5 times higher than that of the control group even at the end of the experiment'....'We would like to have a strategic meeting of both development and co-development managers in one place on the important results and licensing directions obtained through this test.'"

New molecule • PK/PD data • Preclinical • Friedreich ataxia